Investor Relations

Investor Relations

Our Flashpoint. And Beyond…

Dova is a pharmaceutical company focused on acquiring, developing and commercializing drug candidates where there is a high unmet medical need. Our lead drug candidate, DOPTELET® (avatrombopag) is a second generation orally administered thrombopoietin receptor agonist that we are developing for the treatment of thrombocytopenia across many different patient types.